AstraZeneca's Alexion Gets Positive EU Recommendation for Klygefa in Rare Muscle Disease
MT Newswires Live
Yesterday
AstraZeneca (AZN) said Friday that Alexion, AstraZeneca Rare Disease's Klygefa received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval in the European Union.
Klygefa is intended to treat adults with generalized myasthenia gravis, a rare autoimmune disorder characterized by reduced muscle function and severe muscle weakness.
The opinion was supported by data from the phase 3 PREVAIL trial, which the company said demonstrated the efficacy and safety profile of the long-acting C5 complement inhibitor in patients with the disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.